Cagrilintide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Cagrilintide — Long-Acting Amylin / Calcitonin Receptor Dual Agonist (DACRA)

Cagrilintide (AM833) is a long-acting synthetic analog of amylin — the pancreatic beta-cell hormone co-secreted with insulin in response to nutrient intake. Structurally derived from pramlintide (the first approved amylin analog) with strategic amino acid substitutions at positions N14E, V17R, and P37Y, plus lipidation of the N-terminal lysine, cagrilintide achieves resistance to amyloid fibril formation, extended plasma half-life, and once-weekly dosing compatibility. Critically, these modifications make it a non-selective dual agonist at both amylin receptors (AMY1R, AMY3R) and the calcitonin receptor (CTR) — classifying it as a Dual Amylin and Calcitonin Receptor Agonist (DACRA) with a broader pharmacological profile than its predecessor.

Cagrilintide occupies a unique position in the metabolic research landscape: it acts on an entirely different receptor system than GLP-1R, GIPR, and GcgR agonists, engaging brainstem satiety pathways that are anatomically and mechanistically distinct from hypothalamic incretin signaling. This makes it both a standalone research compound of significant interest and a synergistic partner to GLP-1R agonists — a combination under active Phase 3 investigation as CagriSema (cagrilintide + semaglutide).

Why Amylin / Calcitonin Dual Receptor Agonism Matters

The amylin receptor system has long been recognized as a physiologically critical but pharmacologically underexploited satiety pathway. Native amylin acts primarily through the caudal hindbrain — specifically the area postrema (AP) and nucleus tractus solitarius (NTS) — rather than the hypothalamic arcuate nucleus that GLP-1 primarily targets. This neuroanatomical separation means amylin and GLP-1 receptor agonism engage satiety through both distinct and overlapping central circuits, with documented additive effects when both pathways are activated simultaneously.

Research Applications

Cagrilintide is used in studies examining:

• Brainstem amylin receptor biology and the specific contributions of AMY1R vs. AMY3R to body weight regulation and food intake control
• DACRA pharmacology — the mechanistic differences between selective amylin agonism and non-selective amylin/calcitonin receptor co-activation
• Additive and synergistic satiety effects when combined with GLP-1R agonists, particularly in dual-pathway appetite suppression models
• Gastric emptying dynamics and their independent contribution to glucose regulation vs. GLP-1R-mediated effects
• Postprandial glucagon suppression via amylin receptor vs. GLP-1R pathways — distinguishing their relative contributions
• Body composition endpoints under sustained once-weekly amylin receptor stimulation
• Central nervous system satiety circuitry — homeostatic (hypothalamic) vs. hedonic (reward) pathway engagement
• Comparative efficacy benchmarking against GLP-1R mono-agonists, dual incretin agonists, and combination CagriSema protocols

Specifications

Reconstitution

Cagrilintide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 5mg vial + 2mL BAC water = 2.5mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Cagrilintide’s long half-life and once-weekly dosing profile make it one of the more practical amylin analogs for sustained research protocols. Dose escalation is standard in research designs to characterize the dose-response curve and observe receptor adaptation, particularly for GI-related endpoints that tend to attenuate with continued exposure.

Typical titration framework:

• Starting dose: 0.25–0.5mg per administration
• Escalation: Increase by 0.25–0.5mg every 2–4 weeks as tolerated
• Frequency: Once weekly
• Combination protocols: Frequently co-administered with semaglutide or other GLP-1R agonists to study additive/synergistic appetite suppression across dual neural satiety circuits
• Study duration: 12–20 weeks for body composition and metabolic endpoints

Commonly observed effects in research models:

• GI-related (receptor-mediated, typically transient): Nausea, vomiting, decreased appetite, early satiety, constipation — most pronounced during dose escalation; generally attenuate with continued dosing as receptor adaptation occurs
• Metabolic: Dose-dependent reductions in food intake and body weight; postprandial glucagon suppression; fluid balance shifts at higher doses
• Other: Injection site reactions; headache; mild dizziness — profile broadly comparable to GLP-1R agonists given overlapping GI receptor engagement

Research Stacks

Cagrilintide is commonly paired in research settings with:

• Semaglutide — Cagrilintide is a long-acting amylin analogue acting on area postrema and hypothalamic amylin receptors; Semaglutide acts on GLP-1 receptors. Dual-receptor engagement across amylin and incretin axes is the basis of the CagriSema combination studied in clinical metabolic research.
• Tirzepatide — Tirzepatide’s dual GLP-1/GIP agonism is studied alongside Cagrilintide to assess triple-pathway coverage (amylin + GLP-1 + GIP) in energy homeostasis models.
• CJC-1295 No DAC / Ipamorelin — This GHRH/ghrelin receptor blend is paired with Cagrilintide in research models examining concurrent modulation of metabolic and growth hormone secretion axes.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.